Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia

Next Previous
Trial Profile

Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AUTO 1 (Primary)
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Acronyms ALLCAR19

    • Most Recent Events

    • 06 Nov 2019 Interim results (data cut off: 24 July 2019) released at the 61st Annual Meeting and Exposition of the American Society of Hematology
    • 08 Aug 2019 According to an Autolus media release, updated phase I data from the study is expected at The American Society of Hematology (ASH) 2019.
    • 14 May 2019 According to an Autolus media release, updated data from this study is expected by the end of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top